BRCAplus is a next generation sequencing (NGS) panel that simultaneously analyzes 8 breast cancer susceptibility genes, all with published management guidelines. Testing to be considered in Early-onset breast cancer patients who are <45 years of age, Triple negative (ER-/PR-/HER2/neu-) breast cancer patients who are <60 years of age, Patients having Ovarian, Fallopian tube, or primary peritoneal cancer at any age or presence of BRCA1 or BRCA2 mutation in the family. BRCAplus can detect >99.9% of described mutations in the included genes, when present .
Breast Cancer, Ovarian Cancer
ATM (ATM serine/threonine kinase), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), CDH1 (Cadherin 1), CHEK2 (Checkpoint kinase 2), HER-2 (Human epidermal growth factor receptor 2)
See More ...
Next-Generation Sequencing (NGS)